Two is better than one: benefits of VEGF and PDGF inhibition in ovarian cancer.
Sennino
Barbara
B
Cardiovascular Research Institute, Comprehensive Cancer Center, Department of Anatomy, University of California, San Francisco, CA, USA. barbara.sennino@ucsf.edu
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D052157:Aptamers, Nucleotide / Q000627:therapeutic use; D003131:Combined Modality Therapy; D004730:Endothelium, Vascular / Q000187:drug effects; D005260:Female; D006801:Humans; D009389:Neovascularization, Pathologic / Q000188:drug therapy* / Q000378:metabolism; D010051:Ovarian Neoplasms / Q000098:blood supply* / Q000378:metabolism; D020286:Pericytes / Q000187:drug effects; D020574:Proto-Oncogene Proteins c-sis / Q000037:antagonists & inhibitors*; D042442:Vascular Endothelial Growth Factors / Q000037:antagonists & inhibitors*
D020533:Angiogenesis Inhibitors; D052157:Aptamers, Nucleotide; D020574:Proto-Oncogene Proteins c-sis; D042442:Vascular Endothelial Growth Factors